Avid Bioservices Inc (CDMO)

[freethemice]

Another outstanding person who is an investigator on the bavi phase 2 front-line pancreatic trial
is Tony Reid, MD, PhD. Here is the AACR pancreatic cancer conference poster.
http://www.peregrineinc.com/images/stories/pdfs/pancreatic_2012_aacr_poster.pdf
Dr. Reid is professor in the UC San Diego Department of Medicine, Division of Hematology/Oncology

Dr. Reid has published broadly on the use of a new agent for the treatment of these malignancies and conducts a variety of clinical trials that utilize correlative studies to translate between important clinical and basic science observations. He has focused most of his work on early phase therapeutic clinical trials using gene therapy strategies to enhance the immune response to these malignancies.

He received his medical degree from Stanford University, where he also received a Ph.D. in biochemistry. Dr. Reid's Ph.D. thesis focused on the use of interferon to treat cancer and identified pathways involved in the anticancer effects of interferon. These studies led to the recognition that many malignancies lacked pathways that block viral infections. These observations have formed the basis for subsequent research work and clinical trials exploiting the defects in antiviral pathways in tumors to treat tumors with gene therapy vectors.

He was the lead investigator on the original trials using Onyx-015 to treat colorectal cancer and has pioneered the use of adenoviral and vaccinia vectors to the treatment of cancer. Dr. Reid has received national recognition for his work including the awards from the Interferon Society, the International Society of Gene Therapy and the Society for Interventional Radiology.

Dr. Reid has been at the forefront of using interventional radiology to selectively deliver therapeutic directly to the tumor using the tumor's own vascular supply. Finally, Dr. Reid is on the review board of numerous prestigious journals including Nature Cancer Gene Therapy, Gene Therapy and Clinical Cancer Research.